Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer.
Roshan A KarunamuniMinh-Phuong Huynh-LeChun C FanWesley ThompsonRosalind A EelesZsofia Kote-JaraiKenneth Ross MuirArtitaya Lophatananonnull nullJohanna SchleutkerNora PashayanJyotsna Batranull nullHenrik GrönbergEleanor I WalshEmma L TurnerAthene LaneRichard M MartinDavid E NealJenny L DonovanFreddie C HamdyBørge G NordestgaardCatherine M TangenRobert J MacInnisAlicja WolkDemetrius AlbanesChristopher A HaimanRuth C TravisJanet L StanfordLorelei A MucciCatharine M L WestSune F NielsenAdam S KibelFredrik WiklundOlivier CussenotSonja I BerndtStella KoutrosKarina Dalsgaard SørensenCezary CybulskiEli Marie GrindedalJong Y ParkSue A InglesChristiane MaierRobert J HamiltonBarry S RosensteinAna Veganull nullManolis KogevinasKathryn L PenneyManuel R TeixeiraHermann BrennerEsther M JohnRadka KanevaChristopher J LogothetisSusan L NeuhausenAzad RazackLisa F Newcombnull nullMarija GamulinNawaid UsmaniFrank ClaessensManuela Gago-DominguezPaul A TownsendMonique J RoobolWei Zhengnull nullIan G MillsOle Andreas AndreassenAnders M DaleTyler M Seibertnull nullPublished in: Prostate cancer and prostatic diseases (2021)
Incorporating 120 additional SNPs (PHS166 vs PHS46) significantly improved HRs for prostate cancer, while PPV of PSA testing remained the same.